≥99% HPLCPre-filled pen

SLU-PP-332

Name: SLU-PP-332
Brand: Dripfy
Availability: OutOfStock

What it is?

SLU-PP-332 is a pan-ERR (estrogen-related receptor α/β/γ) agonist described in research as an exercise-mimetic, and it sits within the nuclear-receptor and mitochondrial-biogenesis research family. Available data are preclinical and from animal studies only.

Dripfy Advantage

ERR agonism: designed to activate the estrogen-related receptors (ERRα/β/γ)
Mitochondrial biogenesis: linked to the ERR/PGC-1α programme that governs mitochondrial density
Oxidative metabolism: studied for a shift toward fat oxidation and endurance-type metabolism
Exercise-mimetic concept: positioned to mimic aspects of endurance-exercise adaptation (preclinical)

Research & Investigational Focus

Mitochondria: investigated in animal models for mitochondrial biogenesis
Endurance: studied for endurance capacity and fatigue resistance in rodents
Fat oxidation: explored for fat-oxidation and metabolic-fitness pathways

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€499

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

SLU-PP-332

Pan-ERR agonist (exercise-mimetic; investigational) · Pre-filled pen

D· Preliminary evidence

SLU-PP-332 is understood to act as a pan agonist of the estrogen-related receptors, activating the ERR/PGC-1α transcriptional programme that governs mitochondrial biogenesis and oxidative metabolism. In rodent studies this was associated with greater endurance and increased fat oxidation. The evidence is entirely preclinical, and no human trials establish these effects.

Studied use areas

Investigated in animal studies for mitochondrial biogenesis
Studied for endurance capacity and fatigue resistance (rodent models)
Explored for fat-oxidation and metabolic-fitness pathways

Safety & status

Preclinical/animal data only; no human safety or efficacy data exist
Effects of chronic ERR activation in humans are unknown
Use only under physician supervision; not for use in pregnancy or breastfeeding

⚕ Clinical note: SLU-PP-332 is an investigational compound with animal data only and is not an approved therapy; any use is physician-supervised only, and nothing here is medical advice or a dosing guide.

Evidence: Grade D — no reliable human data; preclinical/animal evidence only · References: Billon et al., Journal of Pharmacology and Experimental Therapeutics 2023; Audet-Walsh & Giguère, Acta Physiologica 2015; Fan & Evans, Current Opinion in Cell Biology 2015